However, TP53 mutations have been associated with increased response to chemoimmunotherapy in non-small cell lung cancer47 and mutated TP53 has been shown to induce anti-tumor T cell responses as a neoantigen in ovarian cancer48,49. The gene discussed is TP53; the disease is neoplasm.